Table 4 List of recruiting TCR-T cell clinical trials
Neoantigen | Cancer type | HLA | Cell source | Date | Phase | NCT number | Conditions |
|---|---|---|---|---|---|---|---|
HPV16-E6 | Cervical Carcinoma | HLA-A2 | PB (Patient) | 2022/8/10–2021/8/31 | I/II | NCT05357027 | Recruiting |
HPV16-E7 | HPV-associated Cancers | HLA-A*02:01 | PB (Patient) | 2023/3/7–2025/1/1 | II | NCT05686226 | Recruiting |
HPV-associated Cancers | HLA-A2 | PB (Patient) | 2017/1/27–2026/1/1 | I/II | NCT02858310 | Recruiting | |
HPV16- CRTE7A2-01 | Advanced Cervical, Anal, or Head and Neck Cancers | HLA-A2 | PB (Patient) | 2022/7/17–2024/12 | I | NCT05122221 | Recruiting |
HPV18- HRYZ-T101 | HPV18 positive advanced solid tumor | HLA-A*11:01/02:01/24:02 | PB (Patient) | 2023/3–2025/9 | I | NCT05787535 | Recruiting |
MAGE | Advanced melanoma (MEL) and head-and-neck carcinoma (HNSCC) | HLA-A2 | PB (Patient) | 2020/10/20–2027/10/20 | I/II | NCT04729543 (MAGE-C2) | Recruiting |
Advanced-Stage/Metastatic MAGE-A1+ Solid Tumors | HLA-A*02:01 | PB (Patient) | 2022/7/29–2037/6 | I/II | NCT05430555 (MAGE-A1) | Recruiting | |
Advanced Solid Tumors | HLA-A2 | PB (Patient) | 2019/5/17–2025/7 | I/II | NCT03973333 (MAGE-A4) | Recruiting | |
KRAS | Advanced Pancreatic Cancer | HLA-A*11:01 | TIL (Patient) | 2021/10/21–2025/4 | I/II | NCT04146298 (KRAS G12V) | Recruiting |
Advanced Pancreatic Cancer and Other Solid Tumors | HLA-A*11:01 | PB (Patient) | 2022/6/7–2025/6/30 | I | NCT05438667 (KRAS G12V or G12D) | Recruiting | |
Pancreatic/Gastric/Gastrointestinal /Colon/Rectal Cancer | HLA-A*11:01 | PB (Patient) | 2017/9/21–2028/7/29 | I/II | NCT03190941 (KRAS G12V) | Recruiting | |
Pancreatic/Gastric/Gastrointestinal /Colon/Rectal Cancer | HLA-A*11:01 | PB (Patient) | 2019/4/16–2028/12/1 | I/II | NCT03745326 (KRAS G12D) | Recruiting | |
NY-ESO-1 (CTAG1A) | Locally Advanced Malignant Neoplasm/ Unresectable Malignant NeoplasmSarcoma | HLA-A*02:01 | PB (Patient) | 2017/7/26–2024/8/1 | I | NCT03240861 | Recruiting |
Advanced Soft-tissue Sarcoma | HLA-A*02 | PB (Patient) | 2022/11/11–2028/12/1 | I | NCT05620693 | Recruiting | |
NY-ESO-1 -Expressing Metastatic Cancers | HLA-A*02 | PB (Patient) | 2022/41–2027/12/30 | I/II | NCT05296564 | Recruiting | |
Solid Tumors | HLA-A*02:01 | PB (Patient) | 2022/12–2026/3 | I | NCT05648994 | Recruiting | |
• Soft tissue sarcoma | HLA-A*02:01 | PB (Patient) | 2022/7/8–2024/9/1 | II | NCT05549921 | Recruiting | |
AFP | Advanced hepatocellular carcinoma (HCC) or other AFP expressing tumor Types | HLA-A2 | PB (Patient) | 2017/4/8–2036/7/7 | I | NCT03132792 | Recruiting |
HBV | HBV related hepatocellular carcinoma | HLA-A*02:01/24:02 | PB (Patient) | 2022/4/20–2024/7/1 | I | NCT04745403 | Recruiting |
Hepatocellular carcinoma | HLA-A2 | PB (Patient) | 2019/4/20–2024/6/1 | I | NCT03899415 | Recruiting | |
Hepatocellular carcinoma; Liver cancer, Adult; Liver cell carcinoma | HLA-A *02 | PB (Patient) | 2022/6–2027/5 | I/II | NCT05195294 | Recruiting | |
Hepatitis B Virus related hepatocellular carcinoma; Hepatocellular carcinoma recurrent | HLA-A *02 | PB (Patient) | 2022/10/26–2025/10 | I/II | NCT05417932 | Recruiting | |
Hepatocellular carcinoma | HLA-A*02 | PB (Patient) | 2021/4/14–2023/12 | I | NCT05339321 | Recruiting | |
gp100 (PMEL) | Advanced Melanoma | HLA-A*02:01 | PB (Patient) | 2022/12/19–2027/9 | II/III | NCT05549297 | Recruiting |
Malignant Melanoma | HLA-A*02:01 | PB (Patient) | 2015/11–2025/1 | I/II | NCT02535078 | Recruiting | |
HERV-E | Renal cell carcinoma; Kidney cancer | HLA-A*11:01 | PB (Patient) | 2018/7/20–2032/12/31 | I | NCT03354390 | Recruiting |
EBV | Nasopharyngeal Carcinoma | HLA-A*02:01/24:02/11:01 | PB (Patient) | 2022/12–2030/10 | I | NCT05587543 | Recruiting |
Nasopharyngeal Carcinoma | HLA-A*02:01/24:02/11:01 | PB (Patient) | 2023/3–2023/8 | I/II | NCT04509726 | Recruiting | |
Head and Neck Squamous Cell Carcinoma | HLA-A*02:01/24:02/11:01 | PB (Patient) | 2019/3/1–2024/1/1 | I/II | NCT04139057 | Recruiting | |
EBV Lymphoma; Post-transplant lymphoproliferative disease (PTLD) | HLA-A*02:01/24:02/11:01 | CTLs (Patient) | 2023/5–2025/12 | I/II | NCT05688241 | Recruiting | |
Head and Neck Squamous Cell Carcinoma | HLA-A*02:01/24:02/11:01 | PB (Patient) | 2023/3/1–2027/6/30 | I | NCT05697926 | Recruiting | |
PRAME | Select Advanced Solid Tumors | HLA-A2 | PB (Patient) | 2020/2/25–2026/2 | I/II | NCT04262466 | Recruiting |
HA-1H | Relapsed or persistent hematologic malignancies | HLA-A*02:01 | PB (Patient) | 2020/7/2–2025/7 | I | NCT04464889 | Recruiting |
LAGE-1a | Neoplasms | HLA-A*02:01/02:05/02 | PB (Patient) | 2020/12/21–2025/12/4 | I | NCT04526509 | Recruiting |
Neoplasms | HLA-A*02 | PB (Patient) | 2019/12/31–2026/7/31 | II | NCT03967223 | Recruiting | |
CMV | CMV Infection After Allogenic HSCT | HLA-A*02:01/11:01/24:02 | PB (Patient) | 2021/10/15–2024/12/31 | I | NCT05140187 | Recruiting |
Allogeneic hematopoietic stem cell transplantation; CMV infection | HLA-A*11:01/02:01/24:02 | PB (Patient) | 2021/1/6–2023/8 | I | NCT05089838 | Recruiting | |
KK-LC-1 | Nonsmall cell lung cancer; Solid tumor, Adult | HLA-A*11 | PB (Patient) | 2018/12/1–2033/12/30 | I | CT03778814 | Recruiting |
Gastric/Breast/Cervical/Lung Cancer | HLA-A*01:01 NCT05587543 | PB (Patient) | 2022/9/26–2028/12/31 | I | NCT05483491 | Recruiting | |
Gastric/Breast/Cervical/Lung and other KK-LC-1 positive epithelial cancers | HLA-A*01 | PB (Patient) | 2022/3/8–2026/4/6 | I | NCT05035407 | Recruiting | |
Neoantigen | Advanced Solid Tumor | HLA-A*11:01/02:01/24:02 | PB (Patient) | 2019/1/8–2023/12/1 | I | NCT03891706 | Recruiting |
Malignant Epithelial Neoplasms | HLA-A*11:01/02:01/24:02 | PB (Patient) | 2022/2/8–2027/2/28 | I | NCT04520711 | Recruiting | |
Malignant Epithelial Neoplasms | HLA-A*11:01/02:01/24:02 | PB (Patient) | 2023/3/15–2028/3/15 | I | NCT05349890 | Recruiting | |
Solid tumors | HLA-A*11:01/02:01/24:02 | PB (Patient) | 2022/10/1–2039/6 | I | NCT05292859 | Recruiting | |
Solid tumors | HLA-A*11:01/02:01/24:02 | PB (Patient) | 2021/9/24–2028/5/28 | I | NCT05124743 | Recruiting | |
Solid tumors | HLA-A*11:01/02:01/24:02 | PB (Patient) | 2022/4/4–2029/3 | I/II | NCT05194735 | Recruiting | |
KSH01 | Refractory/Recurrent solid tumors | HLA-A * 02 | PB (Patient) | 2022/8/19–2027/7/31 | I | NCT05539833 | Recruiting |
Solid tumors | HLA-A * 02 | PB (Patient) | 2022/12/11–2027/12/11 | I | NCT05580796 | Recruiting | |
KSX01 | Solid tumors | HLA-A * 02 | PB (Patient) | 2023/3/7–2028/12/31 | I | NCT05811975 | Recruiting |
Mesothelin | Etastatic pancreatic ductal adenocarcinoma | HLA-A*02:01 | PB (Patient) | 2021/12/14–2024/6/1 | I | NCT04809766 | Recruiting |
MCPyV | Metastatic or unresectable merkel cell cancer | HLA-A*02 | PB (Patient) | 2019/7/3–2025/12/15 | I/II | NCT03747484 | Recruiting |